Yaritza Díaz-Algorri1, María Eugenia Lozada1, Sofía M López1, Carlos E Bertrán-Rodríguez1, Cinthia M González-Hernández1, Dilka González2, Cynthia M Pérez-Cardona3, Jessica Hernández1, Carmen Pedrosa2, Doris H Toro2, María González-Pons4, Marcia Cruz-Correa5. 1. University of Puerto Rico Comprehensive Cancer Center, PMB 711 Ave. 89 Ste. 105, San Juan, P.R. 00927-6346. 2. VA Caribbean Healthcare System Casia # 10 San Juan, P.R. 00921-3201. 3. University of Puerto Rico Graduate School of Public Health PO Box 365067 San Juan, P.R., 00936-5067. 4. University of Puerto Rico Comprehensive Cancer Center, PMB 711 Ave. 89 Ste. 105, San Juan, P.R. 00927-6346; University of Puerto Rico School of Medicine PO Box 365067 San Juan, P.R. 00936-5067. 5. University of Puerto Rico Comprehensive Cancer Center, PMB 711 Ave. 89 Ste. 105, San Juan, P.R. 00927-6346; VA Caribbean Healthcare System Casia # 10 San Juan, P.R. 00921-3201; University of Puerto Rico School of Medicine PO Box 365067 San Juan, P.R. 00936-5067. Electronic address: marcia.cruz1@upr.edu.
Abstract
AIMS: There is inconclusive evidence regarding the potential link between diabetes mellitus (DM) and colorectal cancer (CRC). Associations between type 2 DM and colorectal neoplasia (CRN; colorectal cancer and/or adenomas) have not been well studied in Hispanics, an ethnic minority at high risk for type 2 DM. This study aims to assess the association between type 2 DM and CRN in Hispanics. METHODS: Hispanics with incident CRN and colonoscopy-negative controls from 2005 to 2009 were evaluated. Diagnosis of type 2 DM was established by previous medical diagnosis and/or use of DM treatments. Unconditional logistic regression was performed to estimate odds ratios for the association between type 2 DM and CRN. RESULTS: A total of 451 participants (mean age 61.1±11.9years, 59.6 % men) were evaluated (218 with incident CRC, 77 with colorectal adenomas, and 156 colonoscopy-negative controls). The prevalence of type 2 DM in this study was 25.1%. After adjusting for potential confounding variables, women with type 2 DM were 2.74 (95% CI: 0.94-7.99) times more likely to have CRN and 4.83 times more likely to present with proximal colonic CRN (95% CI: 1.25-18.58) than women without type 2 DM. No statistically significant associations were found between type 2 DM and CRN among men. CONCLUSIONS: An increased odds for CRN and proximal location of CRN was observed among Hispanic women with type 2 DM. Since DM is a highly prevalent disease in this population, adherence to routine CRC screening is of outmost importance.
AIMS: There is inconclusive evidence regarding the potential link between diabetes mellitus (DM) and colorectal cancer (CRC). Associations between type 2 DM and colorectal neoplasia (CRN; colorectal cancer and/or adenomas) have not been well studied in Hispanics, an ethnic minority at high risk for type 2 DM. This study aims to assess the association between type 2 DM and CRN in Hispanics. METHODS: Hispanics with incident CRN and colonoscopy-negative controls from 2005 to 2009 were evaluated. Diagnosis of type 2 DM was established by previous medical diagnosis and/or use of DM treatments. Unconditional logistic regression was performed to estimate odds ratios for the association between type 2 DM and CRN. RESULTS: A total of 451 participants (mean age 61.1±11.9years, 59.6 % men) were evaluated (218 with incident CRC, 77 with colorectal adenomas, and 156 colonoscopy-negative controls). The prevalence of type 2 DM in this study was 25.1%. After adjusting for potential confounding variables, women with type 2 DM were 2.74 (95% CI: 0.94-7.99) times more likely to have CRN and 4.83 times more likely to present with proximal colonic CRN (95% CI: 1.25-18.58) than women without type 2 DM. No statistically significant associations were found between type 2 DM and CRN among men. CONCLUSIONS: An increased odds for CRN and proximal location of CRN was observed among Hispanic women with type 2 DM. Since DM is a highly prevalent disease in this population, adherence to routine CRC screening is of outmost importance.
Authors: Katherine Bowers; Demetrius Albanes; Paul Limburg; Pirjo Pietinen; Phil R Taylor; Jarmo Virtamo; Rachael Stolzenberg-Solomon Journal: Am J Epidemiol Date: 2006-07-28 Impact factor: 4.897
Authors: Paul J Limburg; Kristin E Anderson; Trista W Johnson; David R Jacobs; Deann Lazovich; Ching-Ping Hong; Kristin K Nicodemus; Aaron R Folsom Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: CA Cancer J Clin Date: 2010-06-16 Impact factor: 508.702
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: Eunyoung Cho; Stephanie A Smith-Warner; Donna Spiegelman; W Lawrence Beeson; Piet A van den Brandt; Graham A Colditz; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Anthony B Miller; Pirjo Pietinen; John D Potter; Thomas E Rohan; Paul Terry; Paolo Toniolo; Mikko J Virtanen; Walter C Willett; Alicja Wolk; Kana Wu; Shiaw-Shyuan Yaun; Anne Zeleniuch-Jacquotte; David J Hunter Journal: J Natl Cancer Inst Date: 2004-07-07 Impact factor: 13.506
Authors: Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-06 Impact factor: 4.254
Authors: Pooneh Mokarram; Mohammed Albokashy; Maryam Zarghooni; Mohammad Amin Moosavi; Zahra Sepehri; Qi Min Chen; Andrzej Hudecki; Aliyeh Sargazi; Javad Alizadeh; Adel Rezaei Moghadam; Mohammad Hashemi; Hesam Movassagh; Thomas Klonisch; Ali Akbar Owji; Marek J Łos; Saeid Ghavami Journal: Autophagy Date: 2017-02-23 Impact factor: 16.016